COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
12/02/2026
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, [...]
CorMedix to Participate in Upcoming Investor Conferences
12/02/2026
BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes
12/02/2026
NBA legend Muggsy Bogues joins effort to detect and manage coronary artery disease in retired players using AI-powered Heartflow Analysis MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. ( [...]
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
12/02/2026
WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical [...]
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
12/02/2026
MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
12/02/2026
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings [...]
NMDP Appoints Ginna Laport, MD, to New Senior Physician Leadership Role
12/02/2026
Dr. Laport brings 30 years of multi-disciplinary experience across academia, national leadership positions, and industry to advance clinical practice of NMDP cell therapy research MINNEAPOLIS, Feb. 12, 2026 (GLOBE [...]
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
12/02/2026
STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on [...]
Aardvark Therapeutics Announces Leadership Appointments
12/02/2026
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
12/02/2026
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is pleased to announce that [...]
Healthtech Newcomer T·TIME Launches Affordable TRT Alternative
12/02/2026
New men’s telehealth clinic offers injection-free testosterone optimization with enclomiphene, 24/7 medical oversight and all-inclusive monthly pricing AUSTIN, Texas, Feb. 12, 2026 (GLOBE NEWSWIRE) -- T·TIME , a men’s [...]
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
12/02/2026
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
12/02/2026
FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data [...]
Trethera to Highlight Clinical Momentum and Indication Expansion at Biocom Global Partnering & Investor Conference
12/02/2026
LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces an upcoming [...]
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company
12/02/2026
A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO [...]
Picard Medical/ SynCardia Highlights Successful Bridge-to-Transplant Case at UCSF Health Using the SynCardia Total Artificial Heart
12/02/2026
- Successful heart transplant case following an implanted SynCardia total artificial heart reported at hospital with one of the largest heart transplant programs in the country - TUCSON, Ariz., Feb. 12, 2026 (GLOBE [...]
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
12/02/2026
ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
12/02/2026
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 [...]
ImmuneSensor Therapeutics Doses First Patient with Aicardi Goutières Syndrome (AGS) in Phase 1b Clinical Study of cGAS inhibitor, IMSB301
12/02/2026
Trial expansion into AGS and other Type 1 interferonopathies follows successful Phase 1a clinical trial of IMSB301 in healthy volunteers, which demonstrated a well-tolerated safety profile and dose-dependent exposure [...]

Pages